FrancophonIA/ELRC3.0 huggingface dataset:
English: Regarding dental surgery prophylaxis, the results suggested that teicoplanin could be useful.
Slovenian: Glede profilaktične uporabe v zobni kirurgiji so rezultati pokazali, da je teikoplanin lahko uporaben.
English: The information on the measurement of teicoplanin trough serum concentrations by High Performance Liquid Chromatography (HPLC) and Fluorescence Polarization Immunoassay (FPIA) method was considered to be acceptable by the CHMP.
Slovenian: Podatki o merjenju najmanjših serumskih koncentracij teikoplanina z metodo tekočinske kromatografije visoke ločljivosti (HPLC) in imunskih testov s fluorescenčno polarizacijo (FPIA) so bili za odbor CHMP sprejemljivi.
English: The proposed wording was considered to be acceptable by the CHMP.
Slovenian: Predlagano besedilo je bilo za odbor CHMP sprejemljivo.
English: The CHMP concluded that teicoplanin should be indicated in complicated SSTIs i.e. severe cases, but not for the treatment of minor SSTIs in line with the British Society for Antimicrobial Chemotherapy (BSAC) guideline, which does not recommend systemic antibiotics for the treatment of minor SSTIs.
Slovenian: Odbor CHMP je zaključil, da mora biti teikoplanin indiciran pri zapletenih okužbah kože in mehkih tkiv, tj. resnih primerih, vendar ne za zdravljenje manjših okužb kože in mehkih tkiv skladno s smernicami Britanskega združenja za protimikrobno zdravljenje (BSAC), ki ne priporočajo sistemskih antibiotikov za zdravljenje manjših okužb kože in mehkih tkiv.
English: Regarding interactions with teicoplanin, it is known that due to the potential for increased adverse effects, teicoplanin should be administered with caution in patients receiving concurrent nephrotoxic or ototoxic drugs, such as aminoglycosides, amphotericin B, ciclosporin, and furosemide.
Slovenian: Glede medsebojnega delovanja s teikoplaninom je znano, da je treba teikoplanin zaradi možnosti za povečane neželene učinke uporabljati previdno pri bolnikih, ki sočasno prejemajo nefrotoksična ali ototoksična zdravila, kot so na primer aminoglikozidi, amfotericin B, ciklosporin in furosemid.
English: The MAH took the opportunity to harmonise the Quality dossier for Targocid and associated names as part of the referral procedure.
Slovenian: Imetnik dovoljenja za promet z zdravilom je izkoristil priložnost za uskladitev dokumentacije o kakovosti za zdravilo Targocit in povezana imena kot del napotitvenega postopka.
English: The MAH has amended section 4.3 only including hypersensitivity to teicoplanin (or to any of the excipients).
Slovenian: Imetnik dovoljenja za promet z zdravilom je dopolnil poglavje 4.3, tako da ta vključuje samo preobčutljivost na teikoplanin (ali na katero koli od pomožnih snovi).
English: The clinical and bacteriological efficacy of teicoplanin was shown in SSTIs (37.4% of all infection sites) in Study EG-87-42 (European Multicentre Study).
Slovenian: Klinična in bakteriološka učinkovitost teikoplanina je bila ugotovljena pri okužbah kože in mehkih tkiv (37,4 % vseh mest okužb) v študiji EG-87-42 (evropska multicentrična študija).
English: The indication was therefore restricted to complicated urinary tract infections, which was accepted by the CHMP.
Slovenian: Indikacija je bila zato omejena na zapletene okužbe sečil, in jo je odbor CHMP sprejel.
English: In Study EG-87-42 (European Multicentre Study), the clinical and bacteriological efficacy of teicoplanin has been shown in UTI (8% of all infection sites).
Slovenian: V študiji EG-87-42 (evropski multicentrični študiji) je bila klinična in bakteriološka učinkovitost teikoplanina ugotovljena pri okužbah sečil (8 % vseh mest okužb).
English: Section 4.6 - Fertility, pregnancy and lactation The MAH has aligned the text so that it is in line with the CSP and the CHMP Guideline on risk assessment of medicinal products on human reproduction and lactation: From Data to labelling (EMEA/CHMP/203927/2005).
Slovenian: Imetnik dovoljenja za promet z zdravilom je uredil besedilo, tako da je v skladu s smernicami CSP in CHMP za oceno tveganja zdravil na človeško reprodukcijo in dojenje: Od podatkov do označevanja (EMEA/CHMP/203927/2005).
English: However a few cases of endocarditis were included in the open-label studies (EG-87-42 and N-86-04) conducted in support of the initial marketing authorisation.
Slovenian: Kljub temu je bilo v odprte študije (EG-87-42 in N-86-04), ki so bile izvedene v podporo začetnemu dovoljenju za promet, vključenih nekaj primerov endokarditisa.
English: In the current version of EUCAST MIC breakpoints, the resistance breakpoint for Staphylococcus aureus has been reduced to >2 mg/ml to avoid reporting of glycopeptide intermediate resistant Staphylococcus aureus (GISA) isolates, as serious infections with GISA isolates are not treatable with increased doses of vancomycin or teicoplanin.
Slovenian: V trenutni različici mejnih vrednosti MIK EUCAST je bila mejna vrednost odpornosti na bakterijo Staphylococcus aureus znižana na > 2 mg/ml, da bi se izognili poročanju o za glikopeptide intermediarno občutljivih izolatih Staphylococcus aureus (GISA), saj resnih okužb z izolati GISA ni mogoče zdraviti s povečanimi odmerki vankomicina ali teikoplanina.
English: The harmonised dossier was provided for the active substance (teicoplanin) and for products containing this substance: Targocid 100, 200 mg and 400 mg powder for solution for injection/infusion and Targocid 100, 200 mg and 400 mg powder and solvent for solution for injection/infusion.
Slovenian: Usklajena dokumentacija je bila predložena za zdravilno učinkovino (teikoplanin) in zdravila, ki vsebujejo to zdravilno učinkovino: Targocid 100 mg, 200 mg in 400 mg prašek za raztopino za injiciranje/infundiranje in Targocid 100 mg, 200 mg in 400 mg prašek in vehikel za raztopino za injiciranje/infundiranje.
English: The final PL wording was agreed by the CHMP.
Slovenian: Končno besedilo navodil za uporabo je potrdil odbor CHMP.
English: Section 4.5- Interaction with other medicinal products and other forms of interaction The lack of interaction between teicoplanin and other antibiotics, antihypertensives, cardiotropic, antidiabetic agents and anaesthetic agents has been included in the proposed harmonised SmPC.
Slovenian: Poglavje 4.5 - Medsebojno delovanje z drugimi zdravili in druge oblike interakcij V predlagani usklajeni povzetek glavnih značilnosti zdravila je bila dodana odsotnost medsebojnega delovanja med teikoplaninom in drugimi antibiotiki, antihipertenzivi, kartiotropnimi zdravili, antidiabetiki in anestetiki.
English: • Pneumonia and respiratory tract infections
Slovenian: • Pljučnica in okužbe dihalnih poti
English: This PASS is imposed as a condition to the Marketing Authorisation.
Slovenian: Ta študija o varnosti zdravila po pridobitvi dovoljenja za promet je bila sprejeta kot pogoj dovoljenja za promet z zdravilom.
English: In line with the CHMP Guideline on the Evaluation of Medicinal Products indicated for Treatment of Bacterial Infections (CPMP/EWP/558/95 rev 2), it was considered acceptable to further qualify the indications.
Slovenian: V skladu s smernicami za vrednotenje zdravil odbora CHMP, indiciranih za zdravljenje bakterijskih okužb (CPMP/EWP/558/95 rev 2), je bilo sprejeto za nadaljnjo opredelitev indikacij.
English: Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactam antibiotics.
Slovenian: Teikoplanin zavira rast dovzetnih organizmov, tako da posreduje pri biosintezi celične stene na mestu, ki je drugačno od mesta, na katerega so delovali betalaktamski antibiotiki.
English: No pharmacokinetic drug-drug interaction with teicoplanin has been carried out by the MAH, and no published data have been retrieved from the literature.
Slovenian: Imetnik dovoljenja za promet z zdravilom ni izvedel nobenega farmakokinetičnega medsebojnega delovanja med zdravili, predstavljeni pa niso bili nobeni objavljeni podatki iz literature.
English: The MAH has provided evidence from publications in support of the use of teicoplanin in combination with other anti-microbial agents such as aminoglycosides.
Slovenian: Imetnik dovoljenja za promet z zdravilom je predložil dokaze iz publikacij v podporo uporabi teikoplanina v kombinaciji z drugimi protimikrobnimi sredstvi, na primer aminoglikozidi.
English: The harmonization of the pharmacokinetic section in the teicoplanin SmPC is based on the data first provided in the initial marketing authorisation application, and more recent data retrieved from a literature research.
Slovenian: Uskladitev poglavja s farmakokinetiko v povzetku glavnih značilnosti teikoplanina temelji na podatkih, ki so bili predloženi v osnovni vlogi za pridobitev dovoljenja za promet z zdravilom, in novejših podatkih iz raziskav v literaturi.
English: The effect of the higher loading dose (as proposed in section 4.2) on the possible occurrence of adverse drug reactions has also been addressed by the MAH.
Slovenian: Imetnik dovoljenja za promet z zdravilom je obravnaval tudi vpliv višjega polnilnega odmerka (kot je predlagan v poglavju 4.2) na možni pojav neželenih učinkov zdravila.
English: Indeed, in a Cochrane meta-analysis of randomised controlled trials (RCT) in adults and children with CAPD-associated peritonitis, although the primary response and relapse rates did not differ between intraperitoneal (IP) glycopeptide-based regimens compared to first generation cephalosporin regimens, glycopeptide regimens were more likely to achieve a complete cure, and primary treatment failure was less likely to occur with teicoplanin than vancomycin (Wiggins et al. 2008)1.
Slovenian: V Cochranovi metaanalizi randomiziranih kontroliranih preskušanj pri odraslih in otrocih s peritonitisom, nastalim zaradi kontinuirane ambulantne peritonealne dialize, čeprav se delež primarnega odziva in relapsa med intraperitonealnimi (IP) režimi na podlagi glikopeptida in režimi cefalosporina prve generacije ni razlikoval, so glikopeptidni režimi verjetneje dosegli popolno ozdravitev, do neuspeha primernega zdravljenja pa je manj verjetneje prišlo pri teikoplaninu kot pri vankomicinu (Wiggins in sod.
English: Section 5.2 - Pharmacokinetic properties
Slovenian: Poglavje 5.2 - Farmakodinamične lastnosti
English: However the available data suggest that teicoplanin administered IV or IM at dosages of 10 mg/kg every 12 hours for 1 to 5 doses (loading dosage), then 6 to 10 mg/kg once daily, is effective in the treatment of Gram-positive infections such as septicaemia, skin and soft tissue infections, bone and joint infections, lower respiratory tract infections, and in neutropenia and fever, in children.
Slovenian: Kljub temu razpoložljivi podatki nakazujejo, da je teikoplanin, če se daje intravensko ali intramuskularno v odmerkih po 10 mg/kg vsakih 12 ur po 1 do 5 odmerkov (polnitveni odmerek), nato pa po 6 do 10 mg/kg enkrat na dan, učinkovit pri zdravljenju po Gramu pozitivnih okužb, kot so septikemija, okužbe kože in mehkih tkiv, okužbe kosti in sklepov, okužbe spodnjih dihalnih poti ter nevtropenije in povišane telesne temperature pri otrocih.
English: Information on the active substance was submitted in an ASMF.
Slovenian: Informacije o zdravilni učinkovini so bile predložene v glavni dokumentaciji o zdravilni učinkovini (ASMF).
English: The results from the various studies discussed by the MAH suggest that teicoplanin has a place in the management of pneumonia.
Slovenian: Rezultati različnih študij, o katerih je razpravljal imetnik dovoljenja za promet z zdravilom, so pokazali, da teikoplanin sodeluje pri zdravljenju pljučnice.
English: A modified warning regarding hypersensitivity reactions to address the fatal cases that have been reported and to strengthen the possibility of cross hypersensitivity to vancomycin was proposed by the MAH, and accepted by the CHMP.
Slovenian: Imetnik dovoljenja za promet z zdravilom je predlagal spremenjeno opozorilo glede preobčutljivostnih reakcij, ki se nanašajo na smrtne primere, o katerih so poročali, in na okrepitev možnosti navzkrižne preobčutljivosti na vankomicin, kar je odbor CHMP sprejel.
English: The product information was therefore updated to declare the qualitative and quantitative details of the active substance in terms of mass and IU: each vial contains 200mg (or 400) mg teicoplanin equivalent to 200,000 IU (or 400,000 IU).
Slovenian: Podatki o zdravilu so bili zato posodobljeni, tako da določajo kvalitativne in kvantitativne podrobnosti zdravilne učinkovine glede na maso in i. e.: ena viala vsebuje 200 mg (ali 400 mg) teikoplanina, kar je enakovredno 200.000 i. e. (ali 400.000 i. e.).
English: The subcomponents are separated by HPLC according to their polarity.
Slovenian: Podkomponente so ločene s tekočinsko kromatografijo visoke ločljivosti (HPLC) glede na polarnost.
English: The MAH has proposed that a trough plasma concentration of 10mg/l (when measured by high performance liquid chromatography) should be maintained for most infections, and that higher concentrations of 15 to 30mg/l for endocarditis, septic arthritis and osteomyelitis should be considered for severe infections.
Slovenian: Imetnik dovoljenja za promet z zdravilom je predlagal, da je treba za večino okužb vzdrževati najmanjšo koncentracijo 10 mg/l (izmerjeno s tekočinsko kromatografijo visoke ločljivosti) in da je treba pri resnih okužbah razmisliti o višjih koncentracijah od 15 do 30 mg/l za endokarditis, septični artritis in osteomielitis.
English: The wording of the CSP agreed during the PSUR work-sharing procedure (number GR/H/PSUR/0001/001) was considered to be acceptable by the CHMP.
Slovenian: Besedilo CSP, o katerem so se dogovorili med postopkom za delitev dela PSUR (GR/H/PSUR/0001/001), je bilo za odbor CHMP sprejemljivo.
English: Overall, the undesirable effects listed in the CSP agreed during the PSUR work-sharing procedure number GR/H/PSUR/0001/001 have been included in section 4.8 of the proposed harmonised SmPC using the MedDRA Preferred Terms (PTs), and classified by System Organ Class (SOC).
Slovenian: Neželeni učinki, navedeni v CSP, o katerih so se dogovorili med postopkom za delitev dela PSUR številka GR/H/PSUR/0001/001, so bili vključeni v poglavje 4.8 predlaganega usklajenega povzetka glavnih značilnosti zdravila z uporabo priporočenih izrazov po MedDRA in razvrščeni glede na organske sisteme.
English: In conclusion, based on the assessment of the proposals submitted by the MAH and the discussions of the Committee, the CHMP adopted the harmonised product information consisting of the summary of product characteristics (SmPC), labelling and package leaflets, for Targocid and associated names.
Slovenian: Na podlagi ocene predlogov, ki jih je predložil imetnik dovoljenja za promet z zdravilom, in razprav odbora, je CHMP sprejel usklajene podatke o zdravilu Targocid in povezanih imenih, ki jih sestavljajo povzetek glavnih značilnosti zdravila (SmPC), označevanje in navodila za uporabo.
English: As is the current practice in some member states, the maintenance dose of 6-12mg/kg od depending on the type of infection was maintained: 6mg/kg od for complicated skin, soft tissue and urinary tract infections and pneumonia and 12mg/kg od for bone and joint infections and endocarditis.
Slovenian: Kot je trenutna praksa v nekaterih državah članicah, je vzdrževalni odmerek 6 do 12 mg/kg enkrat na dan odvisen od vrste okužbe: 6 mg/kg enkrat na dan za zapletene okužbe kože, mehkih tkiv in sečil ter pljučnico in 12 mg/kg za okužbe kosti in sklepov ter endokarditis.
English: Therefore the indication for the prophylactic use of teicoplanin was not considered to be acceptable by the CHMP.
Slovenian: Indikacija za profilaktično uporabo teikoplanina za odbor CHMP zato ni bila sprejemljiva.
English: The CHMP has requested the MAH to submit a RMP within 6 months of the Commission Decision to adequately address the important potential risks, in particular, the increased frequency of nephrotoxicity and other serious reactions with loading doses of 12mg/kg bid (24mg/kg/day).
Slovenian: Odbor CHMP je zahteval, da imetnik dovoljenja za promet z zdravilom predloži RMP v šestih mesecih po sklepu Komisije, da ustrezno pojasni pomen potencialnih tveganj, zlasti povečano pogostnost nefrotoksičnosti in drugih resnih reakcij s polnilnimi odmerki 12 mg/kg dvakrat na dan (24 mg/kg/dan).
English: The strengths of teicoplanin finished product are conventionally declared and prescribed in terms of mass (e.g. 200 mg and 400 mg), but given the variability of the active substance, it is the potency of the finished product, as determined by microbiological assay and declared in IU (e.g. 200,000 IU or 400,000 IU), that determines the quantitative amount of active substance in the finished product.
Slovenian: Jakosti končnega zdravila teikoplanina so konvencionalno določene in predpisane glede na maso (npr. 200 mg in 400 mg), vendar je zaradi variabilnosti zdravilne učinkovine učinkovitost končnega zdravila, kot je bila določena z mikrobiološkim določanjem in prijavljena v i. e. (npr. 200 000 i. e. ali 400 000 i. e.), tista, ki določa kvantitativno količino zdravilne učinkovine v končnem zdravilu.
English: All the important safety information that has been included in the SmPC has been listed in order of importance: hypersensitivity reactions, infusion related reactions (Red Man Syndrome), severe bullous reactions (including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN)), warning concerning the possible adverse reactions with the higher loading dose of 12mg/kg bid
Slovenian: Vse pomembne varnostne informacije, ki so bile vključene v povzetek glavnih značilnosti zdravila, so bile navedene po pomembnosti: preobčutljivostne reakcije, reakcije, povezane z infundiranjem (sindrom rdečega moža), resne bulozne reakcije (vključno s Stevens-Johnsonovim sindromom in toksično epidermalno nekrolizo), opozorilo glede možnih neželenih učinkov pri polnilnem odmerku, višjem od 12 mg/kg dvakrat na dan (24 mg/kg/dan), trombocitopenija, nefrotoksičnost, ototoksičnost in superinfekcije.
English: Instead, the indication for bacteraemia has been included in accordance with CHMP Guideline on the Evaluation of Medicinal Products Indicated for the Treatment of Bacterial Infections (CPMP/EWP/558/95 rev 2).
Slovenian: Namesto tega je bila vključena indikacija za bakteriemijo skladno s smernicami za vrednotenje zdravil odbora CHMP, indiciranimi za zdravljenje bakterijskih okužb (CPMP/EWP/558/95 rev 2).
English: The antibacterial spectrum has been updated in accordance with the CHMP Note for Guidance on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections (CHMP/EWP/588/95 rev 2).
Slovenian: Protibakterijski spekter je bil posodobljen skladno z navodili za vrednotenje zdravil odbora CHMP, indiciranimi za zdravljenje bakterijskih okužb (CPMP/EWP/588/95 rev 2).
English: The general format proposed by the MAH is in accordance with the EU guideline on the SmPC and therefore considered to be acceptable by the CHMP.
Slovenian: Splošna oblika, ki jo je predlagal imetnik dovoljenja za promet z zdravilom, je v skladu s smernicami EU za splošni povzetek glavnih značilnosti zdravila, zato je za odbor CHMP sprejemljiva.
English: Although no PK-PD modelling has been done, the proposed posology for children is based on Monte Carlo simulations conducted by Lucas et al in 2004 3and Reed in 19974, which was considered to be acceptable by the CHMP.
Slovenian: Čeprav ni bilo izvedeno modeliranje FK/FD, predlagano odmerjanje za otroke temelji na simulacijah Monte Carlo, ki so jih izvedli Lucas in sod.
English: Section 4.7 - Effects on ability to drive and use machines The wording of the CSP agreed during the PSUR work-sharing procedure (GR/H/PSUR/0001/001) was considered to be acceptable by the CHMP.
Slovenian: Poglavje 4.7 − Vpliv na sposobnost vožnje in upravljanja strojev Besedilo CSP, o katerem so se dogovorili med postopkom za delitev dela PSUR (GR/H/PSUR/0001/001), je bilo za odbor CHMP sprejemljivo.
English: Considering that UTIs are mainly caused by gramnegative infections, the MAH was of the view that teicoplanin has a limited role in the management of UTIs.
Slovenian: Ker okužbe sečil v glavnem povzročajo po Gramu negativne okužbe, je imetnik dovoljenja za promet z zdravilom menil, da ima teikoplanin omejeno vlogo pri zdravljenju okužb sečil.
English: The proposed harmonised SmPC reflecting the changes was considered to be acceptable by the CHMP.
Slovenian: Predlagan usklajen povzetek glavnih značilnosti zdravila z vključenimi spremembami je bil za odbor CHMP sprejemljiv.
English: Treatment of Clostridium difficile infection-associated diarrhoea and colitis In the clinical development program of teicoplanin, three open, non-controlled studies were conducted with teicoplanin IV formulation administered orally for antibiotic-associated diarrhea (AAD) and 1 Wiggins KJ, Cochrane Collaboration review and meta-analysis 2008.
Slovenian: Zdravljenje driske in kolitisa zaradi okužbe z bakterijo Clostridium difficile V kliničnem razvojnem programu teikoplanina so izvedli tri odprte nekontrolirane študije z intravensko formulacijo teikoplanina, ki so ga dali peroralno za drisko, povezano z jemanjem antibiotika (AAD), in psevdomembranskim kolitisom (PMC), ki ga povzroča bakterija C. difficile.
English: Based on the Monte Carlo simulations conducted by Yamada et al2 the MAH has proposed a loading dose of 6mg/kg bid for 3 administrations for most infections, and 12mg/kg bid for 3 to 5 administrations for bone and joint infections and infective endocarditis.
Slovenian: Na podlagi simulacij Monte Carlo, ki so jih izvedli Yamada in sod.2, je imetnik dovoljenja za promet z zdravilom predlagal polnitveni odmerek 6 mg/kg dvakrat na dan za tri dajanja pri večini okužb in 12 mg/kg dvakrat na dan za tri do pet dajanj pri okužbah kosti in sklepov ter pri infektivnem endokarditisu.
English: • Bone and joint infections
Slovenian: • Okužbe kosti in sklepov
English: Since this loading dose of 12mg/kg bid (24mg/kg/day) is not well established, a clear statement in section 4.8 has been included in the SmPC that patients should be especially monitored for adverse reactions when higher dosages of 12mg/kg bid (24mg/kg/day) are administered.
Slovenian: Ker ta polnilni odmerek 12 mg/kg dvakrat na dan (24 mg/kg/dan) ni splošno priznan, je bila v poglavje 4.8 povzetka glavnih značilnosti zdravila vključena jasna izjava, da je treba pri uporabi odmerka, višjega od 12 mg/kg dvakrat na dan (24 mg/kg/dan), bolnike še zlasti nadzorovati zaradi možnega pojava neželenih učinkov.
English: The MAH has also agreed to the request made by the CHMP to submit a risk management plan (in which the PASS protocol will be included), in particular, to adequately address the important potential risk of the increased frequency of nephrotoxicity and other serious adverse reactions with loading doses of 12mg/kg bid (24mg/kg/day).
Slovenian: Imetnik dovoljenja za promet z zdravilom se je prav tako strinjal z zahtevo odbora CHMP, da predloži načrt za obvladovanje tveganja (v katerega bo vključen protokol študije o varnosti zdravila po pridobitvi dovoljenja za promet), zlasti za ustrezno preučitev pomembnega morebitnega tveganja povečane pogostnosti nefrotoksičnosti in drugih resnih neželenih učinkov pri polnilnih odmerkih 12 mg/kg dvakrat na dan (24 mg/kg/dan).
English: Since safety data for the loading dose of 12mg/kg bid (24mg/kg/day) is limited, the MAH has agreed to the request made by the CHMP to perform an appropriate post authorisation safety study (PASS) to evaluate the safety of the higher loading dose of 12mg/kg bid (24mg/kg/day).
Slovenian: Ker so varnostni podatki za polnilni odmerek 12 mg/kg dvakrat na dan (24 mg/kg/dan) omejeni, se je imetnik dovoljenja za promet z zdravilom strinjal z zahtevo odbora CHMP, da izvede ustrezno študijo o varnosti zdravila po pridobitvi dovoljenja za promet, da oceni varnost višjega polnilnega odmerka 12 mg/kg dvakrat na dan (24 mg/kg/dan).
English: Further amendments to the wording of the reproductive toxicity section have been included, as requested by the CHMP.
Slovenian: V skladu z zahtevo odbora CHMP so bile vključene tudi nadaljnje spremembe besedila poglavja o toksičnosti za razmnoževanje.